Skip to main content

Table 2 Tumor characteristics

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

 

Data

Numbers (%)

Tumor histology

(n = 107)

Neuroblastoma

99 (92.5)

Ganglioneuroblastoma, intermixed

8 (7.5)

Tumor differentiation

(n = 73)

Undifferentiated

30 (41.2)

Poorly differentiated

35 (47.9)

Differentiated

8 (10.9)

MYCN amplification

(n = 51)

MYCN non-amplified

39 (76.4)

MYCN amplified

12 (23.5)

Shimada histology

(n = 32)

Unfavorable

23 (71.9)

Favorable

9 (28.1)

  1. Notes: Data are presented as number (%) for categorical variables